MBRX News and Press, Moleculin Biotech Inc. From 06/25/20

Moleculin Biotech (NASDAQ: MBRX ) announces data from a presentation entitled, "Targeting Cancer Sanctuary Sites: A Novel Approach to the Treatment of Lung Localized Tumors." More news on: Moleculin Biotech, Inc., Healthcare stocks news, Read more ...

HOUSTON , June 25, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced a presentation at the American A...

NEW YORK, June 23, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its second quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentatio...

Moleculin Biotech (NASDAQ: MBRX ) announces that repeat testing of candidate WP122 confirmed its antiviral potential against a surrogate of SARS-CoV-2 called HCoV-229E. More news on: Moleculin Biotech, Inc., Healthcare stocks news, Stocks on the move, Read more ...

HOUSTON , June 16, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that a repeat of previous in vitro testing has corroborated the antiviral pote...

IZEA Worldwide (NASDAQ: IZEA ) +79% . More news on: IZEA Worldwide, Inc., Second Sight Medical Products, Inc., Immuron Limited, Stocks on the move, , Read more ...

HOUSTON , June 4, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that it has submitted requests to Polish regulatory authorities for approval to...

Moleculin Biotech (NASDAQ: MBRX ) begins patient enrollment in the Emory University Phase 1 clinical trial of WP1066 for the treatment of brain tumors in children. More news on: Moleculin Biotech, Inc., Healthcare stocks news, Read more ...

HOUSTON , June 2, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that recruiting has begun and the first patient has been enrolled in the Emory...

HOUSTON , May 27, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it has received notification...